Patent · US Active

Purified forms of rofecoxib, methods of manufacture and use

US10987337B2 · kind B2 · utility

5Cited by
12References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 16, 2019
Grant dateApr 27, 2021
Priority date
Expiry dateDec 16, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D307/58
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.